MedTrace Logo

Hemostasis During Asparaginase Treatment in Acute Lymphoblastic Leukemia(ALL)

NCT01094392 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 65

Last updated 2021-01-13

No results posted yet for this study

Summary

Asparaginase is an important drug in the treatment of childhood leukemia. One of the rare but severe side effects to the treatment is thrombosis in or outside the central nervous system.

The aim of this study is to investigate and describe the influence on the coagulation parameters during prolonged treatment with asparaginase.

Hopefully this knowledge will help to foresee the risk of thrombosis and thus making it possible to prevent these.

Conditions

Sponsors & Collaborators

  • Aarhus University Hospital

    lead OTHER

Principal Investigators

  • Birgitte K Albertsen, Ph.D. M.D. · Department of Pediatrics, Skejby Hospital, Aarhus, Denmark

Eligibility

Min Age
1 Year
Max Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-03-31
Primary Completion
2018-10-10
Completion
2018-10-10

Countries

  • Denmark

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01094392 on ClinicalTrials.gov